Protein changes in patients with myasthenia gravis taking Ravulizumab
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study looks at protein changes in patients with myasthenia gravis who are taking the medication Ravulizumab. By understanding these changes, researchers hope to learn more about the condition and how the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have generalized myasthenia gravis with a positive AChR antibody test.
- Your doctor must have decided that you need treatment with Ravulizumab as per approved guidelines.
- You must provide signed consent to join the study.
- You must not have other autoimmune diseases, active cancer, or an active infection at the time of sample collection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an early treatment with ravulizumab (a medication that blocks part of the immune system) for people who have recently developed moderate-to-severe generalized myasthenia gravis. The goal is to see if starting treatment early can improve symptoms and daily life.
This study looks for markers that may predict a favorable response to complement inhibitor drugs in people with generalized myasthenia gravis. It aims to identify who might benefit most from this treatment.
This study looks at how well ravulizumab works for people with generalized myasthenia gravis (gMG) who have not tried complement inhibitors before. The goal is to see if this treatment helps improve symptoms in everyday life.
This trial tests whether ravulizumab, a medication that blocks part of the immune system, can improve muscle weakness and fatigue in people with generalized myasthenia gravis (gMG). The study focuses on Chinese adults who have moderate-to-severe MG symptoms despite current treatments.
This study tests whether starting ravulizumab early, after plasma exchange or IVIg, can help people with a severe myasthenia gravis crisis who are in the intensive care unit. It aims to see if it improves their condition.
This study is for people with generalized myasthenia gravis who are already on ravulizumab and a daily steroid. It aims to see if the steroid dose can be safely lowered over time.
Hear when a new Myasthenia Gravis Generalised trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.